AEYE is up +392.76% since Feb ’24 pick Unlock All Top Buy Picks
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of TBPH
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Theravance Biopharma stock price down 1.54% on Wednesday
(Updated on May 22, 2024)

Sell candidate since May 17, 2024 Loss -3.34% PDF

The Theravance Biopharma stock price fell by -1.54% on the last day (Wednesday, 22nd May 2024) from $9.12 to $8.98. During the last trading day the stock fluctuated 5.76% from a day low at $8.95 to a day high of $9.46. The price has fallen in 7 of the last 10 days and is down by -5.37% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -236 thousand shares and in total, 225 thousand shares were bought and sold for approximately $2.02 million.

The stock lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 5.15% during the next 3 months and, with a 90% probability hold a price between $9.01 and $10.66 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

TBPH Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Theravance Biopharma stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $9.33 and $9.34. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, May 15, 2024, and so far it has fallen -8.83%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Theravance Biopharma stock

Theravance Biopharma finds support from accumulated volume at $8.85 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.515 between high and low, or 5.76%. For the last week, the stock has had daily average volatility of 4.20%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (TBPH) For The Upcoming Trading Day Of Thursday 23rd

For the upcoming trading day on Thursday, 23rd we expect Theravance Biopharma to open at $9.13, and during the day (based on 14 day Average True Range), to move between $8.57 and $9.39, which gives a possible trading interval of +/-$0.409 (+/-4.56%) up or down from last closing price. If Theravance Biopharma takes out the full calculated possible swing range there will be an estimated 9.12% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $9.10 (1.34%) than the support at $8.85 (1.45%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Theravance Biopharma stock A Buy?

The Theravance Biopharma stock holds several negative signals and despite the positive trend, we believe Theravance Biopharma will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -2.198 Sell Candidate Unchanged

Predicted Opening Price for Theravance Biopharma of Thursday, May 23, 2024

Fair opening price May 23, 2024 Current price
$9.13 ( 1.65%) $8.98

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for TBPH

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 9.64 7.39 %
R2 9.45 5.20 %
R1 9.33 3.84 %
Current price: 8.98
Support S1 8.93 -0.539 %
S2 8.81 -1.89 %
S3 8.61 -4.08 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 9.69 7.91 %
R2 9.47 5.46 %
R1 9.10 1.34 %
Current price 8.98
Support S1 8.85 -1.45%
S2 8.84 -1.56%
S3 8.64 -3.79%

FAQ

What is the symbol for Theravance Biopharma Stock and on which exchange is it traded?
The symbol for Theravance Biopharma is TBPH and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Theravance Biopharma Stock?
The Theravance Biopharma stock holds several negative signals and despite the positive trend, we believe Theravance Biopharma will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Theravance Biopharma Stock?
Theravance Biopharma Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Theravance Biopharma Stock.

What's the current price of Theravance Biopharma Stock?
As of the end of day on the May 22, 2024, the price of an Theravance Biopharma (TBPH) share was $8.98.

What is the 52-week high and low for Theravance Biopharma Stock?
The 52-week high for Theravance Biopharma Stock is $11.71 and the 52-week low is $8.22.

What is the market capitalization of Theravance Biopharma Stock?
As of the May 22, 2024, the market capitalization of Theravance Biopharma is 443.535M.

When is the next earnings date for Theravance Biopharma?
The upcoming earnings date for Theravance Biopharma is Aug 05, 2024.
Click to get the best stock tips daily for free!

About Theravance Biopharma

Theravance Biopharma Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical tr... TBPH Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT